MHRA will approve DC-Vax. The soon-to-be-released UCLA combination study will show greater than 50% long-term survival of GBM patients. The FDA will not refuse to give GBP patients fantastic odds of conquering GBM because they are not criminally insane. The voices of the frontline oncologists and, above all else, the voices of the patients in the US will demand that the FDA approve DC-Vax. And they will. You can take that to the bank, and we will.
You guys are smart enough to understand this but you will never stop lying to get a paycheck. You dishonor yourselves every day.
Well ex, I'll give you this much. If nothing else, you are consistent. Wrong, but incredibly, incredibly consistent. Still the same old tired argument. Question for you. Once the MHRA approves the DCVax-L MAA, will you argue that they are wrong too, or just drop back to predicting that regardless of that result, none of the other regulators will approve? Just curious.
Lots wrong with all of this but I’ll focus on tissue agnostic designation about which the proteomics study done by NWBO clearly refuted your claim. Individual critical targets were identified that are common to many cancers, viruses and other so “all” also includes specifics which are commonly known targets as well as some previously unknown. Best wishes.
News 
Market Data 
Discover 
